The Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood released a statement following the Obama administration’s release of its FY 2017 budget proposal.
In his statement, Greenwood decries Obama’s action, warning that budget would directly threaten the goal of curing cancer through advances in precision medicine. Specifically, the statement cites the changes to biologic data exclusivity, cuts to Medicare Part D and B, and the emphasis on switching patients to the lowest cost treatment as opposed to the drug that their doctors think are best for them as harmful to medicine innovation and biological products needed to provide the foundation for the “moonshot” initiative.
“In addition, BIO is deeply troubled by the proposed funding cuts for the Project BioShield Special Reserve Fund and the Biomedical Advanced Research and Development Authority’s (BARDA’s) pandemic influenza program, which would undermine the public-private partnership by discouraging manufacturers from investing in research and development of critical medical countermeasures,” Greenwood said.
Greenwood added that the administration’s proposal to reduce the period of regulatory data protection for innovative biologics manufacturers will jeopardize reduced costs, access expansion and overall innovation.
BIO is the world’s largest trade association, representing biotechnology companies, academic institutions, state biotechnology centers and related organizations in the United States.
The ByteDance-owned TikTok faces an uphill battle in the United States after President Joe Biden…
Promising to grow space for integrating and delivering on critical defense programs by more than…
In unsealing a 13-page indictment this week, the U.S. Department of Justice (DOJ) revealed charges…
A bill targeting the illicit fentanyl supply chain, the Fentanyl Eradication and Narcotics Deterrence (FEND)…
In order to move the state closer to federal standards and allow reporting of local…
For the next round of participants in a pilot program to Accelerate the Procurement and…
This website uses cookies.